Difference between revisions of "Enasidenib (Idhifa)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m
Line 1: Line 1:
 
==Mechanism of action==
 
==Mechanism of action==
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=752247 NCI Drug Dictionary]: An orally available inhibitor of isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits IDH2 in the mitochondria, which inhibits the formation of 2-hydroxyglutarate (2HG).
+
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=752247 NCI Drug Dictionary]: An orally available inhibitor of isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits IDH2 in the mitochondria, which inhibits the formation of 2-hydroxyglutarate (2HG).<ref name="insert">[https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf Enasidenib (Idhifa) package insert]</ref>
  
 
==Diseases for which it is used==
 
==Diseases for which it is used==

Revision as of 20:36, 23 April 2018

Mechanism of action

From the NCI Drug Dictionary: An orally available inhibitor of isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits IDH2 in the mitochondria, which inhibits the formation of 2-hydroxyglutarate (2HG).[1]

Diseases for which it is used

History of changes in FDA indication

Also known as

  • Code names: AG-221, CC-90007
  • Brand name: Idhifa